Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)

NCT03380026 is registered in ClinicalTrials.gov with Rochester Skin Lymphoma Medical Group, PLLC as lead sponsor.

NCT NCT03380026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03380026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)
Lead sponsor
Rochester Skin Lymphoma Medical Group, PLLC
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2017
Completion date
December 13, 2020
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma, cutaneous t-cell lymphoma stage i, folliculotropic mycosis fungoides, granulomatous slack skin, mycosis fungoides, mycosis fungoides variant, syringotropic mycosis fungoides, transformed mycosis fungoides